glp 1/gip agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Frontiers | Clinical perspectives on

Radiolabel studies suggest small peptides like exenatide and lixisenatide cross the BBB, while acylated or PEGylated analogues (liraglutide, semaglutide, NLY01) show minimal uptake

Finally, we compare the beneficial effects of GLP-1 receptor agonists and meal-induced gut GLP-1 secretion on overeating-induced obesity and discuss how combining these approaches may complement each others limitations and serve as a promising long-term strategy for preventing and treating obesity

The human body has a complex mechanism for maintaining the levels of blood pressure, including the renin-angiotensin-aldosterone system, natriuretic peptides, endothelial-sympathetic nervous system, and the immune system (134)

doi:10.1111/ejn.14096 2022 The Author(s)

wrote the initial draft with H.M.P., E.F., S.L.B., S.D.G., B.M., and D.C.P

Pharmacol Ther